Improvement of Genome Editing Efficiency in Mammalian Cells by a Refined Uni-Vector Prime Editing System
Summary
Prime editing is an advanced technology in the CRISPR/Cas genome editing field. The original multi-vector method utilized in prime editing has less efficiency and precision and is also inherently difficult in generating homozygous mutations in mammalian cells. To overcome these technical difficulties, a Uni-vector prime editing system containing the major components for prime editing has been constructed in two all-in-one plasmids, pPE3-pPuro and pePE5max-pPuro.
Prime editing is an advanced technology in the CRISPR/Cas genome editing field. The original multi-vector method utilized in prime editing has less efficiency and precision and is also inherently difficult in generating homozygous mutations in mammalian cells. To overcome these technical difficulties, a Uni-vector prime editing system containing the major components for prime editing has been constructed in two all-in-one plasmids, pPE3-pPuro and pePE5max-pPuro. The Uni-vector prime editing plasmids enhance the editing efficiency of prime editing and improve the generation of homozygous mutated mammalian cell lines. The editing efficiency depends on the transfection efficiency. Remarkably, the Uni-vector ePE5max system can achieve a high editing rate even in cell lines that are traditionally difficult to transfect. This Uni-vector approach simplifies the delivery of all the necessary editing components and greatly improves the editing efficiency. This approach represents an advanced progress in the field of prime editing.
Abstract from PubMed (PMID 43015544). This entry was added automatically by our daily literature monitor because it matches the topics we follow; read the full paper at the original source.
Related articles
Orthogonal ensemble and single-particle characterisation of antisense oligonucleotide lipid nanoparticles
Discover nanoLipid nanoparticle-based mRNA delivery system for cancer management
Molecular cancersiRNA-mediated mismatch repair disruption synergizes with oxaliplatin to restore immune surveillance in microsatellite-stable colorectal cancer
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
